Document is current
Any future updates will be listed below
-
Authors
Paramasivan, Naveen Kumar
Sarker, Pallab
Zekeridou, Anastasia
Staff, Nathan P.
Klein, Christopher J.
McKeon, Andrew
Pittock, Sean J.
Dubey, Divyanshu https://orcid.org/0000-0001-6865-9045
-
Funding
Funding for this research was provided by:
Minnesota Office of Higher Education (MN OHE#15)
- License Information
-
More Information
Article History
Received: 18 September 2024
Revised: 4 February 2025
Accepted: 10 February 2025
First Online: 25 February 2025
Declarations
:
: N K Paramasivan, P Sarker and NP Staff report no conflicts interest. A.Zekeridou has patents submitted for Tenascin-R-IgG, PDE10A-IgG, and DACH1-IgG as biomarkers of paraneoplastic neurological autoimmunity. She's received research funding from Roche that was used for neurofilament analysis in this work. She's consulted, without personal compensation, for Alexion Pharmaceuticals. CJ Klein has received personal compensation for his service as a consultant in Takeda, Faze Medicine and Sangamo Therapeutics. A.McKeon. is funded by grants from NIH (RO1NS126227, U01NS120901), and has consulted for Janssen and Roche Pharmaceuticals without personal compensation. Dr. McKeon has patents for Septin-5-IgG and Septin-7-IgG licensed to Euroimmun, a patent for GFAP-IgG issued, a patent for MAP1B-IgG with royalties paid to himself and licensed to Ravo Diagnostika, and patents for CAMKV-IgG, KLCHL11-IgG and PDE10A-IgG pending. S.J. Pittock reports receiving grants, personal fees paid to Mayo Clinic, and nonfinancial support from Alexion Pharmaceuticals, Inc. and MedImmune, Inc./Viela Bio; receiving personal fees from Genentech/Roche, UCB, and Astellas, outside the submitted work; holding patent 8,889,102 (application 12-678350) issued and patent 9,891,219B2 (application 12-573942) issued. D. Dubey has consulted for UCB, Immunovant, Argenx, Arialys and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He is a named inventor on filed patent that relates to KLHL11 as marker of autoimmunity and germ cell tumor. He has patents pending for LUZP4-IgG, cavin-4-IgG and SKOR2-IgG as markers of neurological autoimmunity. He has received funding from the DOD (CA210208 & PR220430), David J. Tomassoni ALS Research Grant Program and UCB.
: All patients provided consent for participation in this study. The study was approved by the Mayo Clinic Institutional Review Board.
